13F-HR filed by Athyrium Capital Management, LP
Athyrium Capital Management, LP filed this 13F-HR for the quarter ended 2023-09-30, filed 2023-11-14, with 6 holding rows worth $113,555,368.
- Accession
- 0001123292-23-000142
- Filer
- CIK 1728001
- Filed
- 2023-11-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q3 2023
A holdings report, 6 entries on the cover page, a total value of $113,555,368 stated on the cover page (in dollars after the unit check, H1), rows summing to $113,555,368 with VALUE read as dollars as filed, 13F file number 028-18509. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| OMEROS CORP | 682143AG7 | NOTE 5.250% 2/1 | 72,979,000 | $44,643,626 | dollars as filed | principal |
| BIORA THERAPEUTICS INC | 74319FAB3 | NOTE 7.250%12/0 | 53,500,000 | $27,960,943 | dollars as filed | principal |
| BIORA THERAPEUTICS INC | 74319F305 | COM | 10,929,762 | $23,717,584 | dollars as filed | |
| Omeros Corp | 682143AE2 | NOTE 6.250%11/1 | 11,005,000 | $11,255,556 | dollars as filed | principal |
| PUMA BIOTECHNOLOGY INC | 74587V107 | COMMON STOCK | 1,792,114 | $4,713,260 | dollars as filed | |
| RVL PHARMACEUTICALS PLC | G6S41R101 | COM | 14,600,444 | $1,264,399 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001123292-23-000142 | this filing | 2023-11-14 | acceptance time not in the bulk data set |